Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody COM701 aims to keep ovarian cancer at bay

NCT ID NCT06888921

Disease control Sponsor: Compugen Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial tests whether the experimental antibody COM701 can delay the return of ovarian cancer in people whose cancer has come back but still responds to platinum chemotherapy. About 60 participants will receive COM701 or a placebo every three weeks as maintenance therapy. The study will measure how long the cancer stays under control and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
COM701 (an experimental antibody)
What this could lead to
If it works, this could provide a new maintenance option to delay ovarian cancer recurrence after chemotherapy.
What could go wrong
This is an early Phase 1/2 trial with only 60 participants, so results may not apply broadly. Side effects are still being studied, and the drug may not slow cancer progression.
Why investors are watching

Compugen, a very small publicly traded company, is testing its experimental antibody COM701 as a maintenance treatment for relapsed platinum-sensitive ovarian cancer. The trial measures whether the drug delays cancer progression and the time until patients need a new treatment. For a micro-cap company, this readout is a major event because a positive result could validate its lead drug candidate, while a negative result would leave the company with few other options.

If it works: If COM701 shows it slows ovarian cancer progression with an acceptable safety profile, Compugen could gain a viable product candidate and attract partnership interest from larger drug companies. A positive result could also support further development in other cancer types.

If it fails: Clinical trials often fail, and this one is small, with only 60 participants planned. If COM701 does not delay progression or causes serious side effects, Compugen would face a significant setback with no approved product and limited financial resources.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has relapsed platinum sensitive epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer * Has completed at least 2 previous courses (i.e. lines) of platinum-containing therapy * For the last chemotherapy course prior to being randomized into the study, must have had a minimum of 4 cycles of a platinum containing regimen and achieved a partial or complete tumor response. * Has received prior maintenance therapy with bevacizumab or a PARP inhibitor if eligible and is not a candidate for, or has declined in writing, bevacizumab or PARP inhibitor therapy. * Have recovered from toxicities of prior chemotherapy or other therapy (to grade 1 or less, except for alopecia and neuropathy recovered to a ≤grade 2). Exclusion Criteria: * Has had 4 or more lines of cytotoxic chemotherapy in total * Is being treated with immunosuppressive doses of systemic medications, such as steroids within 2 weeks before study drug administration * Has had prior treatment with PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors * Presence of radiographic or biopsy proven liver metastases at the beginning or completion of current line of platinum-based chemotherapy. * Drainage of ascites during last 2 cycles of last chemotherapy or any time after completion of the last chemotherapy regimen. * Bowel obstruction in the 6 weeks prior to randomization. * Have known active central nervous system metastases and/or carcinomatous meningitis / leptomeningeal carcinomatosis. * Has active hepatitis B virus (HBV) or hepatitis C virus (HCV), or subjects with human immunodeficiency virus (HIV). * Has active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively. * Has received a live viral vaccine within 30 days of planned start of study treatment or requiring a live vaccine during the study. * Has a history of severe allergic, anaphylactic, or other hypersensitivity reactions to a human or humanized monoclonal antibody (mAb) or allergy to any excipients in the investigational products. * Has any serious or unstable concomitant systemic disorder * Has any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the opinion of the investigator, would make the subject inappropriate for entry into the study. * Is currently participating in or have participated in a clinical study and received an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatment. * Is pregnant or breastfeeding or planning to become pregnant during the period of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer Ovarian cancer recurrent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assuta Medical Center

    RECRUITING

    Ashdod, 7747629, Israel

  • Avera Cancer Institute

    RECRUITING

    Sioux Falls, South Dakota, 57105, United States

  • Centre Eugene Marquis

    RECRUITING

    Rennes, 35042, France

  • Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz

    RECRUITING

    Besançon, France, 25000, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59000, France

  • Corewell Health

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • Georgia Cancer Center at Augusta University

    RECRUITING

    Augusta, Georgia, 30912, United States

  • Gustave Roussy

    RECRUITING

    Villejuif, 94800, France

  • Hadassah, University Hospital Ein Kerem

    RECRUITING

    Jerusalem, 9112001, Israel

  • Hospices Civils de Lyon- Centre Hospitalier Lyon Sud

    RECRUITING

    Pierre-Bénite, 69310, France

  • Institut Paoli-Calmettes

    RECRUITING

    Marseille, 13009, France

  • Institut de Cancerologie de l'Ouest- Site Rene Gauducheau

    RECRUITING

    Saint-Herblain, 44805, France

  • Levine Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center- Main Campus

    RECRUITING

    New York, New York, 10065, United States

  • Northwestern Memorial Hospital

    RECRUITING

    Warrenville, Illinois, 60555, United States

  • OU Health Stephenson Cancer Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run

    RECRUITING

    Hilliard, Ohio, 43026, United States

  • Oncopole Claudius Regaud

    RECRUITING

    Toulouse, France, 31059, France

  • Rambam Health Care Campus

    RECRUITING

    Haifa, 3109601, Israel

  • Shaare Zedek Medical Center

    RECRUITING

    Jerusalem, 9103102, Israel

  • The Chaim Sheba Medical Center

    RECRUITING

    Ramat Gan, 5265601, Israel

  • The Edith Wolfson Medical Center

    RECRUITING

    Holon, 5822012, Israel

  • The University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

  • UPMC Magee- Womens Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • UVA Comprehensive Cancer Center

    RECRUITING

    Charlottesville, Virginia, 22903, United States

  • University of Rochester Medical Center

    RECRUITING

    Rochester, New York, 14642, United States

  • West Cancer Center

    WITHDRAWN

    Germantown, Tennessee, 38138, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.